2 assets in Teratoma With Malignant Transformation

Therapeutic assets addressing Teratoma With Malignant Transformation, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Teratoma With Malignant Transformation	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Teratoma With Malignant Transformation	National Cancer Institute (NCI)	P2	CCC (53)